Cidara Therapeutics announced that the U.S. FDA has granted Breakthrough Therapy designation for CD388.
The designation targets prevention of influenza A and B in adults and adolescents at increased risk due to immune deficiencies, chronic conditions, or vaccine contraindications.
A Non-Vaccine Approach to Influenza
Unlike traditional vaccines, CD388 does not rely on the body’s immune response.
This makes it a viable option for individuals who cannot receive vaccines or respond inadequately.
The Breakthrough designation follows earlier Fast Track recognition, highlighting CD388’s potential as a next-generation influenza prevention therapy.
Supporting Data from NAVIGATE Phase 2b
Phase 2b NAVIGATE trial results showed significant reduction of seasonal influenza cases in healthy, unvaccinated adults aged 18–64.
- Initial data were presented in June 2025
- Full trial findings will be shared at scientific meetings in October
Phase 3 ANCHOR Trial Already Underway
Cidara launched the Phase 3 ANCHOR trial six months ahead of schedule.
- Enrolling older adults >65, including those without specific co-morbidities
- Includes immunocompromised participants and individuals with underlying health conditions
- Evaluates safety and efficacy in high-risk populations
Regulatory Impact
The Breakthrough Therapy designation is intended to accelerate development and FDA review for treatments showing clear potential to improve outcomes in serious conditions.
CD388 may become a transformational non-vaccine option for influenza prevention in vulnerable populations.
